Key result
Gemfibrozil proportionally lowers post-OGTT insulin levels in hypertriglyceridemia.
Why the study?
The relationship between triglyceride reduction and serum insulin levels in hypertriglyceridemic patients and its implications for insulin resistance were unclear.
Does gemfibrozil reduce serum insulin levels and improve insulin sensitivity in hypertriglyceridemic patients?
RCT (n=14)
Double-blind
Does gemfibrozil reduce serum insulin levels and improve insulin sensitivity in hypertriglyceridemic patients?
Reducing triglyceride levels with gemfibrozil in hypertriglyceridemic patients decreases serum insulin levels without changing glucose concentrations, suggesting improved insulin sensitivity.
Answers are grounded in this paper and cite their sources.
Gemfibrozil may improve insulin sensitivity in hypertriglyceridemia; extends evidence linking triglyceride reduction to metabolic benefits.
OBJECTIVE: To determine whether reducing triglyceride concentrations in humans reduces serum insulin levels and consider the implications of this for the insulin resistance of hypertriglyceridemia. RESEARCH DESIGN AND METHODS: Insulin and glucose levels were determined during an oral glucose tolerance test (OGTT) in 14 volunteers who had a range of basal triglyceride levels. A double-blind crossover design was used to study active and placebo gemfibrozil and relate triglyceride changes to insulin and glucose levels. Diet and weight were kept constant. RESULTS: Glucose concentrations during OGTT were the same in both treatment periods. Insulin concentrations were reduced in proportion to reductions in triglyceride. CONCLUSIONS: Triglyceride reduction in hypertriglyceridemic patients is associated with a decrease in serum insulin. This does not appear to be a direct effect of gemfibrozil, because it does not occur without a sufficient fall in triglyceride levels. Because glucose concentration remains the same despite the reduced insulin, the triglyceride reduction may result in greater sensitivity to insulin. Treatment of hypertriglyceridemia may break a vicious and potentially atherogenic cycle of hypertriglyceridemia and hyperinsulinemia.
No takes yet. Share an insight, caveat, or question.
George A. Steiner (1991) conducted an RCT in Hypertriglyceridemia (n=14). Gemfibrozil vs. Placebo was evaluated on Insulin and glucose levels during an oral glucose tolerance test. Gemfibrozil-induced triglyceride reduction in hypertriglyceridemic patients was associated with a proportional decrease in serum insulin concentrations during an oral glucose tolerance test.
Synapse has enriched 10 related papers. Consider them for comparative context: